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Abstract Familial adenomatous polyposis patients are at
risk of duodenal cancer. Surveillance is indicated and the
extent of duodenal polyposis is quantiﬁed by the Spigel-
man staging system. We noticed an impressive increase in
high Spigelman stages over the years and therefore decided
to investigate whether this increase might be due to the
time-lapse since the inception of surveillance or related to
improvements in endoscopic imaging and/or changes in
dysplasia-reporting. Patients who were investigated by the
same endoscopist since 1980 in at least 2 different episodes
of technical improvements were eligible. The period
1980–2009 was divided into 4 episodes using the following
landmarks: replacement of ﬁbre-endoscopes by video-en-
doscopes in 1987, change in processors in 1995, change in
image resolution in 2000, and change in dysplasia-report-
ing in 2006. An increase in Spigelman stages from low
stages (0–II 100%) to high stages (III 28.1%, IV 43.8%)
was seen (median follow-up: 19.5 years). In patients who
progressed, a median of 4 years elapsed before progression
by one stage occurred and 7 years to progress by two
stages. In a mixed-model analysis, both time-lapse and
technical improvements were determinant factors for duo-
denal disease progression. When both factors were intro-
duced in the model, the time-lapse as well as the change in
image resolution and dysplasia-ranking contributed
consistently in increasing Spigelman scores and stages. The
impressive increase in severity of duodenal polyposis is
determined by time-lapse, technological advances and
change in dysplasia-reporting. These results might call for
a revised Spigelman classiﬁcation.
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Introduction
Familial adenomatous polyposis (FAP) is an inherited
autosomal dominant condition caused by a mutation of the
adenomatous polyposis coli (APC) gene on the long arm of
chromosome 5 [1, 2]. The most conspicuous feature of the
diseaseistheearlydevelopmentofthousandsofadenomasin
thecolon.Colorectalcancerdevelopsinvirtuallyallaffected
members by the 5th decade of life unless prophylactic
colectomy is performed. Extra-colonic intestinal manifesta-
tionsincludefundicglandpolyposisandantrumadenomasin
the stomach and duodenal and small intestinal adenomas.
Afterprophylacticsubtotalcolectomy,theriskofsubsequent
upper gastrointestinal cancer or desmoid disease is greater
than the risk of cancer in the retained rectal segment after
ileorectal anastomosis [3–6]. The absolute risk of duodenal
cancer over lifetime is estimated to be 3–5% [7–10].
This has resulted in a discussion about the relevance of
surveillance of the duodenum and its beneﬁts in terms
of survival [10–17]. In an attempt to quantify the extent of
duodenal polyposis, a staging system has been developed
by Spigelman et al. [18]. This classiﬁcation includes
endoscopic features (number and size of adenomas) and
histopathological characteristics (type of adenoma and
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never been validated, it has facilitated a better under-
standing of the natural history of duodenal polyposis and
has attempted to link the stage of duodenal polyposis to the
severity of the disease. It has been accepted as the gold
standard for risk-stratiﬁcation of duodenal cancer. The
different stages are used to determine the interval of sur-
veillance and the need for intervention.
In the last 2 decades, an impressive technical develop-
ment in the endoscopic equipment has resulted in improved
endoscopic imaging quality. Furthermore, the Vienna
classiﬁcation has changed the nomenclature of dysplasia
into negative for dysplasia, low grade dysplasia (LGD) and
high grade dysplasia (HGD) [19]. Only Saurin et al. [9]
have indicated how they changed their Spigelman scoring
according to the new Vienna classiﬁcation, scoring 1 point
for LGD and 3 points for HGD.
Overtheyears,wehavetheimpressionthatthenumberof
high Spigelman stages is increasing. We postulated several
possible reasons for this increase such as the increased age
and prolonged survival of FAP patients, the differences in
ratings between consecutive endoscopists, the technical
improvement in endoscopic imaging and the recent changes
in the dysplasia classiﬁcation for pathologists. A last pos-
sible explanation might be the difference in type of the en-
doscopes used for the assessment. The Spigelman
classiﬁcation was originally developed for only that part of
the duodenum that is visible by a sideward-viewing endo-
scope, i.e. the ﬁrst and second part of the duodenum [18],
whereas a larger area up to the duodenojejunal ligament can
be visualized with a regular forward-viewing endoscope.
The aim of this study was to examine whether the
increase in Spigelman stages was due to
1. the time lapse since the start of upper digestive tract
surveillance;
2. the improved endoscopic image quality
a. between ﬁbre-endoscopes and video-endoscopes
b. due to changes in processors
c. between low and high resolution systems;
3. the change in the classiﬁcation of dysplasia.
Materials and methods
Patients
At our institute, a tertiary referral academic centre, sur-
veillance of FAP patients started in 1975. To exclude a
possible inﬂuence of different endoscopic assessments and
ratings by consecutive endoscopists, we included only
patients who were investigated by one endoscopist (E.M-V)
since 1980 over time and who were examined in at least 2
different episodes (see below). In the period 1992–2000,
patients participated in the DAF trial (duodenal adenoma-
tosis in FAP patients), which required a 2-yearly upper
endoscopic surveillance with a forward-viewing endoscope
with multiple biopsies taken from the polyps if present and
with multiple random biopsies in the absence of polyps
[7, 20]. Since 1997, the Spigelman stage was assessed using
both a forward-viewing and a sideward-viewing endoscope,
enabling staging both with and without the papillary region.
Patients remained in the study till the censory date of
January 1, 2009 or the date of decease. Patients who
underwent surgery, polypectomy or endoscopic mucosal
resection of duodenal polyps or the papilla, which might
have resulted in down-staging [21], were included until the
date of the intervention.
Methods
The period between 1980 and 2009 was divided into 4 epi-
sodes using the following landmarks: the replacement of
ﬁbre-endoscopes by video-endoscopes in 1987, the change
from EVIS-100 to EVIS-130/140 (End Video Inform Sys-
tem,Olympus,Tokyo,Japan)processorsin1995,thechange
from Low Resolution to High Resolution (EVIS-EXERA-
160; End Video Inform System—EXelentERA, Olympus,
Tokyo, Japan) endoscopes in 2000 and the Vienna classiﬁ-
cation of dysplasia introduced in 2006 (Fig. 1). The Spig-
elman score and stage were calculated without inclusion of
the papilla. Since 1997, a separate Spigelman score and
stage was calculated which included the papilla, which in
case of a papillary adenoma and in case of a higher grade of
dysplasia in biopsies of the papilla contributed to a higher
Spigelman score and stage. For this separate analysis, only
patients with an endoscopy before and after 1997 were
included. After the introduction of the Vienna classiﬁcation
[19], dysplasia scores according to Saurin et al. [9] were
used: scoring 1 point for LGD and 3 points for HGD.
Statistics
Patient characteristics are described as median and ranges.
Patients entered and left the study at different times, the
latter in case of death or endoscopic or surgical interven-
tions. Some patients had a consistent 2-yearly follow-up,
dictated by the DAF study, whereas others had their fol-
low-up as indicated by the Spigelman stage (Table 1).
Therefore, a linear mixed model analysis with ﬁxed and
random effects was used. For each comparison models with
different correlation structures were built and the best ﬁt-
ting model with the lowest 2-restricted Log Likelihood was
taken. Covariance types used in the model building were
variance components and autoregressive covariance
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123structures. The dependent variables included the Spigelman
score (0–12 points) and in a secondary analysis the Spig-
elman score with inclusion of the papilla. Fixed factors
were the time lapse since the start of screening and the 4
period indicators. A random intercept and a random slope
per patient were included to account for the correlations
between measurements belonging to the same patient.
First, each of the ﬁxed factors was introduced into a single
model followed by a model that included the ﬁxed factor
time lapse and one of the 4 period indicators. To avoid
intercorrelation of the period indicators with the time
variable, the 4 period indicators were not simultaneously
offered to the model. Despite its low number of categories
(0–IV stages) a similar conﬁrmatory linear mixed model
analysis was performed on the Spigelman stages. A P value
of\0.05 was considered signiﬁcant.
Results
In our centre, 160 patients with FAP are under surveillance.
Of this cohort, 32 patients were eligible as they underwent
an endoscopy in at least 2 separate periods and were all
investigated by the same endoscopist (E.M-V). In this
group of 32 patients, colectomy was performed at a median
age of 28 years and screening of the upper digestive tract
started a median of 10 years later (Table 2). The median
follow-up was 19.5 years (range, 8–28 years); patients
received a median of 6.5 (2–17) endoscopies for surveil-
lance of the duodenum resulting in a total of 210 endos-
copies for analysis.
Fifteen patients did not complete the follow-up period
till the censory date of January 1, 2009. Five patients (4
males) died, one at 40 years because of cancer at the
ileoanal anastomosis, one patient died from a jejunal can-
cer at the age of 57 years and one from a peripapillary
cancer at the age of 59 years. A female patient died at the
age of 55 years from lung cancer, a male of 81 years died
from lung emphysema. Ten patients (5 males, 5 females)
had surgery or endoscopic intervention for duodenal ade-
nomatosis. Two patients underwent a Whipple procedure
and two a pancreas-preserving duodenectomy. One patient
underwent a polypectomy of a duodenal polyp, two
patients a papillectomy because of a growing papillary
Fig. 1 Mean Spigelman score
over time and the inﬂuences of
changes in equipment and
pathology
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123adenoma and three an endoscopic mucosal resection
because of high grade dysplasia in a duodenal adenoma.
These interventions were all performed in patients with
Spigelman scores 10–12 and thus Spigelman stage IV in
the period 2005–2009.
This cohort of 32 patients started their surveillance at a
median age of 38 (13–65) years and at their ﬁrst assessment
most had Spigelman stage 0 or I (65.6%), the remainder
(approximately one-third) stage II, and none of the patients
had stage III or stage IV (Table 3). The last endoscopy for
this analysis was performed at a median age of 50 (25–80)
years. At that time, 9 patients had Spigelman stage 0–II
(28.2%), 28.1% stage III and 43.8% stage IV. In 2 patients
the inclusion of the papilla resulted in a higher stage,
progressing from stage II to IV.
The progression in duodenal adenomatosis within
patients over time was studied as well. Two patients, 53
and 65 years old at their ﬁrst screening endoscopy, had no
duodenal polyps for 20 and 15 years, respectively. The ﬁrst
patient then progressed over 6 years to a stage IV polyposis
at the age of 79, the other patient died from emphysema at
the age of 80 years without polyps. Spigelman stages of 9
patients ﬂuctuated between I and II (3 patients), II and III
(4 patients) and III and IV (2 patients) over a median period
Table 1 Scoring system related to the Spigelman classiﬁcation to
estimate the severity of duodenal adenomatous polyposis and the risk
of duodenal cancer development. The number and size of the polyps,
the histological characteristics and the degree of dysplasia are given a
score between 0 and 3. The 4 scores are summed up and the overall
score determines the Spigelman stage and the suggested follow-up
Score Number of polyps Size of polyps Histological characteristics Degree of dysplasia
0 0 No polyps No adenomas No dysplasia
1 1–4 1–4 mm Tubular adenoma Mild dysplasia
2 5–20 5–10 mm Tubulovillous adenoma Moderate dysplasia
3 [20 [10 mm Villous adenoma Severe dysplasia
Spigelman score Spigelman stage Suggested follow-up
0 0 Every 5 year
1 - 4 I Every 5 year
5 ? 6 II Every 2 years
7 ? 8 III Every year
9 - 12 IV Every 6 months
Table 2 Characteristics of
patients entering the study on
duodenal adenomatous
polyposis
N (male/female) 32 (16/16)
Age at colectomy-years (median and range) 28 (9–52)
Age when starting upper digestive tract screening-years median and range) 38 (13–65)
Age at last upper digestive tract screening-years (median and range) 50 (25–80)
Age at censory date (January 1 2009) (N = 27)-years (median and range) 52.0 (33–81)
Positive family history N (%) 24 (75)
APC mutation known N (%) 19 (59.4)
First operation
Subtotal colectomy and ileorectal anastomosis (IRA) N (%) 20 (62.5)
Proctocolectomy with ileal pouch anal anastomosis (IPAA) N (%) 11 (34.4)
Proctocolectomy with ileostoma N (%) 1 (3.1)
Operation status in 2009 N (%)
Subtotal colectomy and ileorectal anastomosis (IRA) N (%) 11 (34.4)
Proctocolectomy with ileal pouch anal anastomosis (IPAA) N (%) 13 (40.6)
Proctocolectomy with ileostoma N (%) 8 (25.0)
Total number of endoscopies N 210
Number of endoscopies per patient (median and range) 6.5 (2–17)
Fundic glands present N (%) 23 (71.9)
Total follow-up in years (median and range) 19.5 (8–28)
Interrupted study due to endoscopic intervention N (%) 10 (31.3)
Interrupted study due to death N (%) 5 (15.6)
Participant of DAF study N (%) 8 (25.0)
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123of 23 (range, 4–28) years with a median number of 8 en-
doscopies (range, 4–17). In 21 patients (66%) a steady
progression in stage was noticed. The time interval
between two subsequent endoscopies when a change by
one stage or by two stages was reported could be calculated
for 49 episodes (Table 4). A median of 4 (range, 1–18)
years elapsed in case of a one-stage change and a median of
7 (range, 1–28) years in case of a two-stage change.
Inﬂuence of time lapse on the course of the Spigelman
score and stage
The number of years since the year of the start of the ﬁrst
screening endoscopy was a signiﬁcant determining factor
in the Spigelman score and stage over the years
1980–2009. Each year contributed 0.30 points to the
Spigelman score and 0.12 to the stage (Table 5).
Inﬂuence of the endoscopic equipment on the course
of the Spigelman score and stage
A signiﬁcant effect of the change from ﬁbre-endoscope to
video-endoscope, from EVIS-100 to EVIS-130 and from
Low to High Resolution equipment on the Spigelman score
and stage was found. The older equipment resulted in a
lower Spigelman score and stage (Table 5). For the ﬁbre-
endoscope and for the lower resolution endoscope the
estimate effects in lowering the Spigelman score and stage
were greater than for the EVIS-100.
Inﬂuence of changed assessment of dysplasia
on the course of the Spigelman score and stage
The change in the assessment of dysplasia according to the
Vienna classiﬁcation from 4 classes into 3 classes had a
signiﬁcant effect on the Spigelman score and Spigelman
classiﬁcation. The reporting of 4 classes of dysplasia
resulted in a -3.37 points lower Spigelman score and
a -1.47 lower Spigelman stage (Table 5).
Combined inﬂuences of time lapse, endoscopic
equipment and changed assessment of dysplasia
on Spigelman score and stage
When the effects of improved endoscopic equipment and
changed dysplasia assessment were modulated by the time
lapse, the time turned out to be dominant and signiﬁcant in
its effect on the Spigelman score and stage. Per year, the
time lapse contributed between 0.24 and 0.36 points and
between 0.09 and 0.15 stages (Table 5, Fig. 1). As to the
endoscopic equipment a consistent and independent effect
was seen with the EVIS processors and the Lower Reso-
lution endoscopes. Also, the changed dysplasia rating
inﬂuenced the Spigelman score and stage independently
from the time lapse. Per year the time lapse contributed
0.27 points and 0.10 stages, whereas the old classiﬁcation
of dysplasia gave a lowering of the Spigelman score and
stage by -1.33 points and -0.70 stages.
Combined inﬂuence of time lapse, endoscopic
equipment and changed assessment of dysplasia
on Spigelman score and stage with inclusion
of the papilla
The inclusion of the papilla in the Spigelman score and
classiﬁcation resulted in a higher score and stage in 31
endoscopies. An inﬂuence of the endoscopic equipment
independent from the time lapse was only present for the
Table 3 Comparison of Spigelman stages at ﬁrst and last endoscopy
First endoscopy
at entry N (%)
Last endoscopy at the
completion of the study
N (%)
Stage 0 17 (53.1) 1 (3.1)
Stage I 4 (12.5) 2 (6.3)
Stage II 11 (34.4) 6 (18.8)
Stage III 0 9 (28.1)
Stage IV 0 14 (43.8)
All 32 32
Median age (range)
at the ﬁrst endoscopy
Median age (range)
at the last endoscopy
Stage 0 38 (13–65) 80
Stage I 25.5 (18–39) 59; 60
Stage II 43 (25–51) 37.5 (25–68)
Stage III – 40 (29–66)
Stage IV – 54.5 (32–79)
All 38 (13–65) 50 (25–80)
Table 4 Duration of interval that elapses when the Spigelman stag-
ing system increases by one stage or by two stages
Median
years
Range
years
Overall one stage higher (36 episodes) 4 1–18
Change from stage 0 to I (6 episodes) 3.5 3–18
Change from stage I to II (6 episodes) 5 1–10
Change from stage II to III (15 episodes) 4 1–15
Change from stage III to IV (9 episodes) 4 1–8
Overall two stages higher (13 episodes)
without intercurrent endoscopy
7 1–28
Change from 0 to II (8 episodes) 6.5 1–28
Change from I to III (1 episode) 11
Change from II to IV (4 episodes) 4 1–13
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123Low and High Resolution endoscopes. Per year, the time
lapse contributed 0.27 points and 0.11 stages to the Spig-
elman score and stage, respectively. The use of lower
resolution endoscopes resulted in a lower Spigelman score
(-1.21 points) and a lower stage (-0.52 stages). Similarly,
both the time lapse and the changes dysplasia assessment
ranking had a signiﬁcant impact. While the time lapse per
year enhanced the Spigelman score with 0.30 points and
the Spigelman stage with 0.12 stages, the old classiﬁcation
of dysplasia lowered the score and stage by -1.46 points
and -0.78 stages, respectively.
Discussion
In this cohort of 32 patients, none presented with Spigel-
man stage III and IV disease at the start, whereas after a
median of 19.5 years 72% of them have advanced duode-
nal polyposis stage III or IV. This is also reﬂected by the
high number of patients (31%) that underwent duodenal
intervention and the one patient (3%) who died from a
periampullary cancer despite surveillance. This increase in
duodenal polyposis over time has been conﬁrmed by sev-
eral others [7, 9, 14, 21]. In previous studies, time since the
diagnosis of FAP, age and the Spigelman stage at initial
endoscopy were found to be determining factors for the
severity of duodenal adenomatosis rather than gender or
the site of the APC mutation [2, 7, 9, 22, 23].
In this study we demonstrated that improvements in
endoscopic equipment over the years 1980–2009 have
contributed to the Spigelman score and stage. For instance,
whitish discoloured mucosa (harbouring adenomatous tis-
sue) is increasingly more reported with the use of endo-
scopes with improved resolution, resulting in increased
Table 5 Statistical analysis of the inﬂuence of time lapse, technical improvements and changes in pathology in the Spigelman score and stage
Dependent
factor
Fixed factor* -2 log
likelihood
Signiﬁcance
P value
Estimated effect (95%
CI)**
Signiﬁcance
P value
Estimated effect (95%
CI)**
First factor First factor Second factor Second factor
Spigelman
score
Time lapse 912.19 \0.001 0.30 (0.24/0.36)/year)
Scope change 1 1,007.91 \0.001 -2.98 (-4.04/-1.91)
Scope change 2 995.44 \0.001 -2.60 (-3.35/-1.84)
Scope change 3 957.54 \0.001 -3.17 (-3.80/-2.54)
PA change 994.19 \0.001 -3.37 (-4.32/-2.41)
Time lapse and scope 1
change
908.14 \0.001 0.33 (0.26/0.40)/year 0.07 1.05 (-0.09/2.19)
Time lapse and scope 2
change
906.04 \0.001 0.36 (0.28/0.43)/year 0.014 1.14 (0.23/2.06)
Time lapse and scope 3
change
906.47 \0.001 0.24 (0.17/0.31)/year 0.018 -0.98(-1.79/-0.17)
Time lapse and PA
change
903.29 \0.001 0.27 (0.20/0.33)/year 0.003 -1.33 (-2.20/-0.46)
Spigelman
stage
Time lapse 562.55 \0.001 0.12 (0.09/0.14)/year
Scope change 1 648.02 \0.001 -1.17 (-1.62/-0.72)
Scope change 2 638.99 \0.001 -1.00 (-1.32/-0.68)
Scope change 3 597.67 \0.001 -1.30 (-1.57/-1.04)
PA change 627.07 \0.001 -1.47 (-1.87/-1.07)
Time lapse and scope 1
change
559.12 \0.001 0.14 (0.11/0.17)/year 0.037 0.52 (0.03/1.01)
Time lapse and scope 2
change
554.80 \0.001 0.15 (0.12/0.18)/year 0.002 0.62 (0.23/1.02)
Time lapse and scope 3
change
557.95 \0.001 0.09 (0.06/0.12)/year 0.013 -0.44 (-0.80/-0.10)
Time lapse and PA
change
551.20 \0.001 0.10 (0.08/0.13)/year \0.001 -0.70 (-1.08/-0.33)
* Scope 1 change: the replacement of ﬁbre-endoscopes by video-endoscopes, scope 2 change: the change from EVIS-110 to EVIS-130–140
processors, scope 3 change: the replacement of Low Resolution by High Resolution endoscopes; PA change: replacement of the 4-grade
dysplasia ranking by the 3-grade ranking
** CI conﬁdence interval, …/year increase of Spigelman in score or stage per year time lapse
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123numbers of ‘‘polyps’’ for the Spigelman classiﬁcation. Also
the red discoloured central excavation in slightly raised,
irregular shaped lesions at the apex of valvular folds are
more readily appreciated with the newer endoscopes. If the
time lapse since the ﬁrst endoscopy, thus the ageing of the
population, was also taken into consideration, only the
High Resolution endoscopes showed an independent effect
on the Spigelman score and stage. This effect was more
impressive when the papilla was also included. Since we
know that with older endoscopic equipments a normal
appearing papilla showed adenomatous tissue in 50% of
cases [18, 24, 25], this is probably due to the better visu-
alization of the papilla resulting in better targeted sampling
of an abnormal papilla. The change in the assessment of
dysplasia had also an independent effect on the Spigelman
score and stage.
In our cohort, the progression from one Spigelman stage
to the next was slow with a median of 4 years, a ﬁnding
generally conﬁrmed by others. Heiskanen et al. [8] found a
mean interval for the progression of stage 0 to stage I of
5.7 years, from I to II 4 years, from II to III 6 years and
from III to IV 11 years (Table 6). Both Burke et al. [26]
and Matsumoto et al. [27] also suggested that the
worsening of duodenal polyposis with advancing age is a
relatively slow process. Others report that duodenal ade-
nomatosis is progressive in about 16–40% of cases or not at
all [16, 25–31]. Alternatively, stable disease in 60% or
even regression in 26% after an interval of 40 months has
also been described [16, 26]. In our cohort two patients had
no duodenal polyps for 15 and 20 years. Nine patients
showed ﬂuctuations of one stage over a median period of
23 years. Twenty-one patients (66%) did progress over
time with a median of 7 years before 2 higher stages were
reached.
The percentage of patients with advanced disease may
seem higher than reported in previous series. This seems to
result from several methodological differences. Our fol-
low-up was rather long with a median of 19.5 years, all
endoscopies were performed at least with a forward-
viewing (and since 1997 also sideward-viewing) endo-
scope, resulting in inspection of a larger area of the duo-
denum than in the original Spigelman publication [18].
Several investigators have shown the presence of ade-
nomatous tissue in random biopsies [7, 18, 20, 24, 32].
Likewise, because we participated in the DAF study, we
were used to take many biopsies and thus discovered
Table 6 Data on the distribution of Spigelman stage and changes therein in prospective studies [7–9, 14, 16, 18, 20, 21]
Stage 0 (%) Stage I (%) Stage II (%) Stage III (%) Stage IV (%)
Spigelman 1989 n = 102 2 18.60 34.30 34.30 10.80
Mean age stage 0–IV 33.5–51 years
Nugent 1994 n = 70 4.30 17.10 25.70 38.60 14.30
Mean age stage 0–IV 40.7–50.4 years
Bu ¨low 1995 n = 312 30.10 17.30 26.60 16.70 9.30
Mean age stage 0–IV 37–40 years
Bu ¨low 2004 n = 366 33.60 15.00 26.50 17.40 7.40
Mean age 37 years, FU 7.6 years
Heiskanen n = 98 45.90 34.70 14.30 3.10 2.00
Mean interval (years) between one stage change 5.7 4 6 11
Groves 2002 n = 114 2.60 13.2 38.60 36.00 9.60
Median age stage 0–IV 34–58 years
Stage progression N after 10 years of FU 0 3 7 5 4
Saurin 2002 n = 41 0 12.20 17.10 34.10 36.60
Saurin 2004 n = 35 0 8.50 31.40 45.70 14.20
Mean age 37 years, FU 4 years 0 8.50 17.10 31.40 42.80
Lepisto 2009 n = 129 30.20 36.40 19.40 12.40 1.60
Mean age 37 years
FU 8.5 years, n = 100 8 17 41 18 16
Mean age 46 years
Current study Start n = 32, mean age 36.8 years 53.10 12.50 34.40 0 0
FU 18.4 years, N = 32, mean age 50 years 3.10 6.30 18.80 28.10 43.80
Mean interval (years)
–between one stage change 6.7 5.2 5.1 4.3
–between two stage change 11 11 5.5
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123adenomatous tissue in previously unsuspected areas.
Finally, also the inspection of the papilla with targeted
biopsies contributed to a higher Spigelman score, a ﬁnding
conﬁrmed by others [33].
As shown by our study as well as by others, the
cumulative lifetime risk of developing duodenal adenomas
is high, between 90 and 97% [2, 7, 8]. The cumulative risk
of developing stage IV duodenal adenomatosis varies
between 11 and 50% [7–10, 14, 34]. Given that all FAP
patients will develop duodenal adenomas which progress to
stage IV in 30% of cases, the incidence of duodenal cancer,
i.e. 3–5% in most studies, is surprisingly low [7–10].
Our ﬁndings of higher stages due to improved visibility
and histology suggest that we might overestimate the
clinical signiﬁcance by using the Spigelman system.
Therefore, we recently reviewed the data of our 160 FAP
patients [35]. In 45 patients the classiﬁcation was not yet
known, mainly because of the young age of the subjects
being children and grandchildren of our index cases. In the
remaining 115 patients 67 (58%) were classiﬁed as Spig-
elman III and IV and over one-third (26 patients) under-
went endoscopic papillectomy, endoscopic mucosal
resection and/or duodenectomy for severe duodenal pol-
yposis. Although the Spigelman staging system has facili-
tated a better understanding of the natural history of
duodenal polyposis, its use for risk-stratiﬁcation has never
been validated in a prospective study. In the light of the
above ﬁndings, we believe that the Spigelman classiﬁcation
should be reﬁned with a more balanced importance of
polyp number, size and histology and including the papilla.
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